Find Academic Supervisors

Kristian HelinView profile

Professor

• Cancer biology
• Epigenetics
• Stem cells
• +5 more

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

David S. EisenbergView profile

Professor

• Protein Aggregation
• Amyloid Structures
• Prion Diseases
• +5 more

David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.

• Nuclear Magnetic Resonance (NMR)
• In vivo imaging
• MRI pulse sequence development
• +7 more

Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.

Christopher E. NelsonView profile

Assistant Professor

• Gene therapy
• Regenerative medicine
• Genome editing
• +7 more

Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.

Laura SoltView profile

Associate Professor

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +5 more

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

Daniel RazanskyView profile

Professor

• Biomedical Imaging
• Functional Imaging
• Molecular Imaging
• +7 more

Daniel Razansky is a Full Professor at the Department of Information Technology and Electrical Engineering, ETH Zurich, leading the Professorship for Biomedical Imaging. His research spans engineering, physics, biology, and medicine, focusing on developing advanced in vivo imaging tools like optoacoustic tomography and ultrasound neuromodulation. His recent work emphasizes multi-scale functional and molecular imaging , with applications in neuroscience , Alzheimer’s disease , and stroke diagnostics . Collaborations include National Tsing Hua University and the EU Horizon consortium SWEEPICS. Current projects target hybrid imaging systems (e.g., MRI-MSOT) and image-guided neuromodulation. Scientific awards include the IPPA James Smith Prize for his contributions. His lab has secured significant grants, including a $2.5M NIH award and SNSF funding. He mentors PhD students like Quanyu Zhou and Eva Remlova, who have received accolades for their research. The Razansky Lab at ETH Zurich’s Preclinical Imaging Center explores medical microrobotics , dynamic fluid flow imaging , and neuroimaging techniques , aiming to bridge engineering with clinical applications.

• Neuroimaging
• Functional Neuroimaging
• Biomedical Imaging
• +3 more

Evelyn Lake is an Associate Professor in the Department of Radiology and Biomedical Imaging at Yale University, with affiliations to the Wu Tsai Institute and Yale Biomedical Imaging Institute. Her research focuses on functional neuroimaging, particularly using rodent models to study brain connectivity, neurovascular coupling, and disorders like Alzheimer’s disease and autism spectrum disorder. PhD in Medical Biophysics, University of Toronto (2016) Postdoctoral Associate, Yale University (2019) BSc (Honors) in Biophysics, University of Guelph (2010) Her work spans multimodal imaging techniques (e.g., simultaneous Ca2+ and fMRI), examining how genetic mutations (e.g., PTEN, KATNAL2) affect cerebrospinal fluid dynamics and neuronal connectivity. She investigates longitudinal changes in Alzheimer’s models and methodological aspects of animal neuroimaging, such as sample size optimization and awake imaging protocols. Recent publications highlight her contributions to understanding autism-related white matter abnormalities, transdiagnostic connectome predictive modeling, and the impact of neurovascular uncoupling in awake mice. Collaborations include Todd Constable, Francesca Mandino, Xilin Shen, and Xenophon Papademetris.

Istvan ModyView profile

Professor

• Neuroscience
• Neurology
• Pharmacology
• +12 more

Istvan Mody is a Professor at the University of California, Los Angeles (UCLA) with appointments in the Department of Neurology and Department of Physiology . His research focuses on synaptic signaling in health and disease, including mechanisms of GABAergic transmission, calcium homeostasis, and their roles in neurological disorders such as epilepsy, Alzheimer's disease, Huntington's disease, stress, alcoholism, and postpartum depression. He utilizes advanced techniques like patch-clamp electrophysiology, neuroanatomical and immunohistochemical methods, and molecular biology in animal models and human brain tissue . Research Interests: Dr. Mody investigates the physiology, pharmacology, and pathology of synaptic transmission and extrasynaptic receptor activation , with a particular emphasis on GABA(A) receptors and their subunit-specific modulation. His work explores how disruptions in excitation-inhibition balance contribute to neurological diseases, including mechanisms of tonic inhibition , calcium signaling , and neurosteroid interactions . He also studies the effects of chronic stress and hormonal fluctuations on neural excitability and behavior. Publications Trends: Recent studies highlight his work on gamma oscillations in Alzheimer's models, microglial dynamics , and rehabilitation strategies for stroke. His lab develops optical tools like dqGEVI for neuronal activity monitoring and investigates human brain organoids to model network dysfunction in epilepsy and intellectual disability. Laboratory Location: 635 Charles Young Dr S, Los Angeles, CA 90095, United States.

• Medical Imaging
• Radiology
• Neuroscience
• +4 more

Uwe Himmelreich is a Full Professor at the Faculty of Medicine, KU Leuven , leading the Biomedical MRI unit. He is actively involved in the Medical Imaging Division , KU Leuven Brain Institute , KU Leuven Institute for Integration of Micro- and Nano-scale Technologies , and KU Leuven Cancer Institute . Role: Full Professor and Head of Biomedical MRI Affiliations: Faculty of Medicine, Medical Imaging Division, LBI, LIMNI, LKI His research spans neuroscience , cardiovascular imaging , and nano/micro-scale technologies . Key projects include: MindMAP: Radiotherapy-induced neurotoxicity in juvenile brains Preclinical cancer models for oral tumors Quantitative T2 mapping of lung disease in murine models Neuroinflammation and cognitive decline in cryptococcosis Resistance training effects on cortical thickness in aging cohorts His work integrates MRI , multi-photon microscopy , and novel contrast agents for longitudinal in vivo studies. Methodologies include vascular density mapping , proton therapy verification , and preclinical radiotherapy evaluation . Notable contributions include: 2025: JAK/STAT inhibition in malaria-induced inflammation 2025: Manganese-enhanced MRI for cardiac injury 2025: Quantitative lung imaging at 9.4T 2024: IVIM as vascular density marker in rat brain 2024: Phase-change ultrasound agents for proton therapy

Ilse DewachterView profile

Professor

• Alzheimer's Disease
• Neurodegenerative Diseases
• Therapeutic Development
• +6 more

Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.

• Oncology
• Sarcoma Research
• Precision Medicine
• +3 more

Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.

Xenophon PapademetrisView profile

Professor

• Medical Image Analysis
• Machine Learning
• Biomedical Software Development
• +7 more

Xenophon Papademetris is a Professor of Biomedical Informatics & Data Science and Radiology & Biomedical Imaging at Yale School of Medicine. He serves as Associate Director of Biomedical Imaging Data Sciences at Yale Biomedical Imaging Institute and directs the Medical Software and Medical Artificial Intelligence Certificate Program. PhD in Electrical and Information Sciences from Yale University (2000) BA from Cambridge University (1994) Postdoctoral Fellowship at Yale University (2002) His research focuses on medical image analysis, machine learning, and biomedical software development. He has developed tools like BioImage Suite Web and contributed to standards committees at the Association for the Advancement of Medical Instrumentation (AAMI). His work spans modalities including MRI, CT, PET, and optical imaging. Recent publications emphasize neuroimaging analysis, explainable AI in healthcare, and multimodal data integration across species. He leads NIH-funded research under the BRAIN Initiative (R24 MH114805) and has authored a textbook on Medical Software published by Cambridge University Press. IEEE Senior Member Yale Brown-Coxe Postdoctoral Fellowship Harding Bliss Prize for Excellence in Engineering He directs the BioImage Suite Project, creating web-based image analysis tools using JavaScript and WebAssembly. His teaching includes both academic courses and a Coursera program on Medical Software with over 14,000 enrollments.

Mirko TrajkovskiView profile

Professor

• Metabolic Diseases
• Obesity
• Insulin Resistance
• +5 more

Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.

Elisabeth BinderView profile

Professor

• Psychiatric Disorders
• Gene-Environment Interactions
• Epigenetics
• +4 more

Prof. Dr. Dr. Elisabeth Binder is the Director of the Max Planck Institute of Psychiatry and leads the Max Planck Research Group "Genes and Environment" in Munich, Germany. Her research focuses on molecular mechanisms underlying psychiatric disorders, particularly how genetic and environmental factors interact in disease development. Education: Medicine (University of Vienna), Neuroscience (Emory University) Affiliations: Max Planck Institute of Psychiatry, International Max-Planck Research School Translational Psychiatry, Graduate School of Systemic Neuroscience Research Interests: Elisabeth Binder investigates gene-environment interactions in psychiatric disorders, emphasizing early trauma and stress response. Her work employs next-generation sequencing, epigenetic analysis, and induced pluripotent stem cells to identify biological markers for disease prevention and treatment. Scientific Awards: Theodore Reich Young Investigator Award (2010) Max Hamilton Memorial Prize (2012) Eva King-Killam Research Award (2016) Carus Medal (2017) Ron the Kloet Award for Stress Research (2019) Leadership Roles: She is a member of the German National Academy of Sciences (Leopoldina), a Fellow of the American College of Neuropsychopharmacology, and serves on multiple international advisory committees and executive boards in psychiatry and neuroscience.

• Neurodegenerative Diseases
• Motor Neuron Disease (MND)
• Frontotemporal Dementia (FTD)
• +7 more

Dr. Rebecca San Gil is a Lecturer at the School of Medical Sciences , University of Sydney, Australia. She leads the NeuroMolecular Discovery Group within the Neuroscience theme and is a member of the Charles Perkins Centre . Her research focuses on the molecular mechanisms underlying neurodegenerative diseases such as motor neuron disease (MND) and frontotemporal dementia (FTD) , with an emphasis on protein aggregation, stress responses, and therapeutic discovery. PhD, University of Wollongong (2018) Postdoctoral Research, Queensland Brain Institute (2018–2025) Endeavour Research Fellow (University College London) Her research spans molecular biology , neurosciences , and biochemistry , integrating techniques like genome-wide CRISPR screening , multi-omics analysis , and translational research . Key themes include the role of molecular chaperones , heat shock response , and protein folding dynamics in mitigating neurodegeneration. Dr. San Gil’s recent publications (2016–2025) highlight her work on TDP-43 pathology , heat shock proteins , and therapeutic strategies across ALS/FTD models. She has received awards such as the FightMND Early Career Research Fellow and the Sydney Dementia Network Future Research Leader Award (Travel Support Scheme) in 2025. Scientific Awards : FightMND Early Career Research Fellow, Sydney Dementia Network Future Research Leader Award (2025) Dr. San Gil actively mentors researchers like Celine CHYE and collaborates with institutions globally. Her team welcomes new members to explore neurodegenerative disease biology and therapeutic discovery .